natgillin/translations-raw huggingface dataset:
c P-værdi for superioritetstest, der sammenligner procentandelen af virologisk succes, var fra CMH-testen (CochranMantel-Haenszel) stratificeret efter det tidligere behandlingsregime (EFV/FTC/TDF, FTC/TDF plus boosted atazanavir eller E/C/F/TDF).
c P-value for the superiority test comparing the percentages of virologic success was from the CMH (Cochran-Mantel-Haenszel) test stratified by the prior treatment regimen (EFV/FTC/TDF, FTC/TDF plus boosted atazanavir, or E/C/F/TDF).
I studier hos virologisk supprimerede voksne patienter var der gennem 96 ugers behandling minimale ændringer eller fald i albuminuri(UACR) hos patienter, der fik Odefsey, sammenlignet med stigninger i forhold til baseline hos patienter, der forblev på FTC/RPV/TDF eller EFV/FTC/TDF.
In studies in virologically suppressed adult patients, through 96 weeks of treatment there were minimal changes or decreases in albuminuria (UACR) in patients receiving Odefsey compared with increases from baseline in patients who stayed on FTC/RPV/TDF or EFV/FTC/TDF.
De hyppigst rapporterede bivirkninger i kliniske studier hos behandlingsnaive patienter, som fik rilpivirinhydrochlorid i kombination med emtricitabin + tenofovirdisoproxilfumarat, var kvalme (9 %), svimmelhed (8 %), unormale drømme (8 %), hovedpine (6 %), diarré (5 %) og søvnløshed (5 %).
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking rilpivirine hydrochloride in combination with emtricitabine + tenofovir disoproxil fumarate were nausea (9%), dizziness (8%), abnormal dreams (8%), headache (6%), diarrhoea (5%) and insomnia (5%).
Seponering af behandlingen med Odefsey hos patienter, som samtidig er inficerede med hiv og HBV, kan være forbundet med svær, akut eksacerbation af hepatitis.
Discontinuation of Odefsey therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
Lægemidler, der inducerer P-gp- og BCRP-aktivitet (f.eks. rifampicin, rifabutin, carbamazepin, phenobarbital) forventes at nedsætte absorptionen af tenofoviralafenamid, hvilket fører til en nedsat plasmakoncentration af tenofoviralafenamid, hvilket kan forårsage en svigtende terapeutisk virkning af Odefsey samt udvikling af resistens.
Medicinal products that induce P-gp activity (e.g., rifampicin, rifabutin, carbamazepine, phenobarbital) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of Odefsey and development of resistance.
Legemsvægten påvirkede ikke rilpivirins farmakokinetik hos pædiatriske patienter i studiet C213 (33 til 93 kg),
There was no impact of body weight on rilpivirine pharmacokinetics in paediatric patients in Study C213 (33 to 93 kg), similar to what was observed in adults.
4.8), og der skal gives støttende standardbehandling efter behov, herunder observation af patientens kliniske status og monitorering af vitale parametre og EKG (QT-interval).
If overdose occurs the patient must be monitored for evidence of toxicity (see section 4.8), and standard supportive treatment applied as necessary including observation of the clinical status of the patient and monitoring of vital signs and ECG (QT interval).
Ingen speciel risiko for mennesker blev vist i konventionelle studier af karcinogenicitet og reproduktionsog udviklingstoksicitet.
No special hazard for humans was revealed in conventional studies of carcinogenic potential and toxicity to reproduction and development.
I kliniske studier hos mennesker resulterede en 10 mg oral dosis af tenofoviralafenamid givet sammen med emtricitabin, cobicistat og elvitegravir, i tenofovirdiphosphatkoncentrationer > 4 gange højere i PBMC'er og > 90 % lavere koncentrationer af tenofovir i plasma sammenlignet med en 245 mg oral dosis af tenofovirdisoproxil (som fumarat) givet sammen med emtricitabin, cobicistat og elvitegravir
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide given with emtricitabine, cobicistat and elvitegravir resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) given with emtricitabine, cobicistat and elvitegravir.
I betragtning af alle tilgængelige in vitro-data og data genereret med behandlingsnaive patienter kan følgende resistensassocierede mutationer i hiv 1 RT, hvis de er til stede ved baseline, påvirke aktiviteten af Odefsey: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L og kombinationen af L100I og K103N.
Considering all of the available in vitro data and data generated in treatment-naïve patients, the following resistance-associated mutations in HIV-1 RT, when present at baseline, may affect the activity of Odefsey: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L and the combination of L100I and K103N.
Efter flere doser med oral administration af emtricitabin til 20 hiv 1-inficerede forsøgspersoner var (gennemsnitlig ± SD) AUC (areal under kurven) for plasmakoncentration/tid over et doseringsinterval på 24 timer 10,0 ± 3,1 t•µg/ml.
Following multiple dose oral administration of emtricitabine to 20 HIV-1 infected subjects, the (mean ± SD) area-under the plasma concentration-time curve over a 24-hour dosing interval (AUC) was 10.0 ± 3.1 h•µg/mL.
Tenofovir har aktivitet mod hiv 1, hiv 2 og HBV.
Tenofovir has activity against HIV-1, HIV-2 and HBV.
Samtidig administration af Odefsey og andre lægemidler, som hæmmer P-gp (f.eks. ketoconazol, fluconazol, itraconazol, posaconazol, voriconazol, ciclosporin), forventes at øge absorptionen og plasmakoncentrationen af tenofoviralafenamid.
Co-administration of Odefsey with other medicinal products that inhibit P-gp and BCRP activity (e.g., ketoconazole, fluconazole, itraconazole, posaconazole, voriconazole, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide.
I løbet af 144 ugers behandling seponerede ingen forsøgsdeltager E/C/F/TAF på grund af en behandlingsrelateret renal bivirkning, hvorimod 12 forsøgsdeltagere seponerede E/C/F/TDF (p < 0,001).
Through 144 weeks of treatment, no subject discontinued E/C/F/TAF due to a treatment-emergent renal adverse event compared with 12 subjects who discontinued E/C/F/TDF (p < 0.001).
De hyppigst rapporterede manifestationer er hæmatologiske forstyrrelser (anæmi, neutropeni), metaboliske forstyrrelser (hyperlaktatæmi, hyperlipasæmi).
The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia).
Tabel 5: Virologiske resultater fra studierne GS-US-366-1216 og GS-US-366-1160 ved uge 48a og 96b
Table 5: Virologic outcomes of Studies GS-US-366-1216 and GS-US-366-1160 at Weeks 48a and
I et separat fase 1-studie udelukkende med emtricitabin var gennemsnitlig systemisk eksponering for emtricitabin højere hos patienter med svært nedsat nyrefunktion (estimeret CrCl < 30 ml/min) (33,7 µg•time/ml) end hos forsøgspersoner med normal nyrefunktion (11,8 µg•time/ml).
In a separate Phase 1 study of emtricitabine alone, mean systemic emtricitabine exposure was higher in patients with severe renal impairment (estimated CrCl < 30 mL/min) (33.7 µg•h/mL) than in subjects with normal renal function (11.8 µg•h/mL).
I forhold til fastende tilstand førte administration af Odefsey sammen med mad hos raske, voksne forsøgspersoner til en øget eksponering for rilpivirin (AUC) på 13-72 %.
Relative to fasting conditions, the administration of Odefsey to healthy adult subjects with food resulted in increased rilpivirine exposure (AUC) by 13-72%.
Den mediane (Q1, Q3) ændring fra baseline ved uge 144 i total-kolesterol:HDLkolesterol-ratioen var 0,2 (-0,3; 0,7) hos patienter, der fik FTC + TAF, og 0,1 (0,4; 0,6) hos patienter, der fik FTC + TDF (p = 0,006 for forskellen mellem behandlingsgrupperne).
Median (Q1, Q3) change from baseline at Week 144 in total cholesterol to HDL-cholesterol ratio was 0.2 (-0.3, 0.7) in patients receiving FTC + TAF and 0.1 (-0.4, 0.6) in patients receiving FTC + TDF (p = 0.006 for the difference between treatment groups).
Antacida bør kun administreres enten mindst 2 timer før eller mindst 4 timer efter Odefsey.
Antacids should only be administered either at least 2 hours before or at least 4 hours after Odefsey.
Odefseys sikkerhed og virkning hos børn, der er yngre end 12 år eller vejer < 35 kg, er endnu ikke klarlagt.
The safety and efficacy of Odefsey in children younger than 12 years of age, or weighing < 35 kg, have not yet been established.
Tenofoviralafenamid er ikke en hæmmer af CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 eller CYP2D6 in vitro.
Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP2D6 in vitro.
e Inkluderer patienter, der udgik af andre grunde end en bivirkning (AE), død eller manglende eller tab af effekt; f.eks. trak samtykke tilbage, manglende opfølgning, etc.
e Includes patients who discontinued for reasons other than an adverse event (AE), death, or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.
Hjælpestoffer, som behandleren skal være opmærksom på Hver tablet indeholder 189,8 mg lactosemonohydrat.
Each tablet contains 189.8 mg lactose monohydrate.
Baseret på disse begrænsede data lignede sikkerhedsprofilen for emtricitabin + tenofoviralafenamid i kombination med elvitegravir og cobicistat som en fastdosis kombinationstablet hos patienter med samtidig hiv/HBVinfektion den for patienter med hiv 1-monoinfektion.
Based on these limited data, the safety profile of emtricitabine + tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet, in patients with HIV/HBV co-infection, was similar to that in patients with HIV-1 monoinfection.
I studier hos behandlingsnaive voksne patienter var E/C/F/TAF forbundet med en mindre påvirkning af renale parametre (målt efter 144 ugers behandling som eGFRCG og forholdet mellem protein og kreatinin i urinen [UPCR] og efter 96 ugers behandling som forholdet mellem albumin og kreatinin i urinen [UACR]) sammenlignet med E/C/F/TDF.
In studies in treatment-naïve adult patients, E/C/F/TAF was associated with lower impact on renal safety parameters (as measured after 144 weeks treatment by eGFRCG and urine protein to creatinine ratio [UPCR] and after 96 weeks treatment by urine albumin to creatinine ratio [UACR]) compared to E/C/F/TDF.
Emtricitabintriphosphat hæmmer kompetitivt hiv 1 revers transkriptase (RT), hvilket resulterer i kædeblokering af deoxyribonukleinsyre (dna).
Emtricitabine triphosphate competitively inhibits HIV-1 reverse transcriptase (RT), resulting in deoxyribonucleic acid (DNA) chain termination.
I løbet af 96 uger med behandling med rilpivirin blev der observeret gennemsnitlige ændringer på 0,1 mg/dl (interval: -0,3 mg/dl til 0,6 mg/dl) for kreatinin og -13,3 ml/min/1,73 m2 (interval:63,7 ml/min/1,73 m2 til 40,1 ml/min/1,73 m2) for eGFR.
Over 96 weeks of treatment with rilpivirine mean changes of 0.1 mg/dL (range: -0.3 mg/dL to 0.6 mg/dL) for creatinine and -13.3 mL/min/1.73 m2 (range: -63.7 mL/min/1.73 m2 to 40.1 mL/min/1.73 m2) for eGFR were observed.
Odefsey bør ikke administreres sammen med andre lægemidler, der indeholder tenofoviralafenamid, lamivudin, tenofovirdisoproxil eller adefovirdipivoxil (se pkt.
Odefsey should not be co-administered with other medicinal products containing tenofovir alafenamide, lamivudine, tenofovir disoproxil or adefovir dipivoxil (see section 4.5).
Odefsey bør generelt undgås, men kan anvendes med forsigtighed hos voksne med nyresygdom i slutstadiet (estimeret CrCl < 15 ml/min) i kronisk hæmodialyse, hvis de potentielle fordele opvejer de potentielle risici (se pkt.
Odefsey should generally be avoided but may be used with caution in adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis if the potential benefits outweigh the potential risks (see section 4.2).
Mens De tager Odefsey
While you are taking Odefsey
Dyrestudier indikerer ikke direkte eller indirekte skadelige virkninger med hensyn til reproduktionstoksicitet (se pkt.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3) with the components of Odefsey.
Indlægsseddel: Information til brugeren Odefsey 200 mg/25 mg/25 mg filmovertrukne tabletter emtricitabin/rilpivirin/tenofoviralafenamid Dette lægemiddel er underlagt supplerende overvågning.
Package leaflet: Information for the user Odefsey 200 mg/25 mg/25 mg film-coated tablets emtricitabine/rilpivirine/tenofovir alafenamide This medicine is subject to additional monitoring.
Croscarmellosenatrium Lactose (som monohydrat) Magnesiumstearat Mikrokrystallinsk cellulose Polysorbat 20
Croscarmellose sodium Lactose (as monohydrate) Magnesium stearate Microcrystalline cellulose Polysorbate 20
Administration af Odefsey sammen med lægemidler, der hæmmer CYP3A-enzymaktivitet, er blevet observeret at øge plasmakoncentrationerne af rilpivirin.
Co-administration of Odefsey with medicinal products that inhibit CYP3A enzyme activity has been observed to increase rilpivirine plasma concentrations.
Nedsat nyrefunktion Dosisjustering af Odefsey er ikke nødvendig hos voksne og unge (i alderen mindst 12 år og med en legemsvægt på mindst 35 kg) med en estimeret kreatininclearance (CrCl) ≥ 30 ml/min.
No dose adjustment of Odefsey is required in adults or in adolescents (aged at least 12 years and of at least 35 kg body weight) with estimated creatinine clearance (CrCl) ≥ 30 mL/min.
Odefsey er ikke blevet undersøgt hos patienter med svært nedsat leverfunktion (Child-Pugh klasse C); derfor frarådes det at bruge Odefsey hos patienter med svært nedsat leverfunktion (se pkt.
Odefsey has not been studied in patients with severe hepatic impairment (Child Pugh Class C); therefore, Odefsey is not recommended for use in patients with severe hepatic impairment (see sections 4.4 and 5.2).
Når der korrigeres for proteinbinding, er plasmakoncentrationer af ubundet (frit) tenofoviralafenamid sammenlignelige ved svært nedsat leverfunktion og normal leverfunktion.
When corrected for protein binding, unbound (free) plasma concentrations of tenofovir alafenamide in severe hepatic impairment and normal hepatic function are similar.
De må ikke amme, mens De er i behandling med Odefsey.
Do not breast-feed during treatment with Odefsey.
Den mediane alder var 36 år, 78 % var mænd, 62 % var hvide og 24 % sorte/afroamerikanere.
The median age was 36 years, 78% were male and 62% White and 24% Black/African American.
Farmakokinetik, sikkerhed, tolerabilitet og virkning af en dosis en gang dagligt på 25 mg rilpivirin, i kombination med et investigatorvalgt BR med to NRTI'er, blev evalueret i studiet TMC278-C213, et åbent fase 2-studie med en enkelt arm af antiretroviral-naive hiv 1-inficerede pædiatriske patienter i alderen 12 til < 18 år, som vejede mindst 32 kg.
The pharmacokinetics, safety, tolerability, and efficacy of rilpivirine 25 mg once daily, in combination with an investigator-selected BR containing two NRTIs, were evaluated in Study TMC278-C213, a single-arm, open-label Phase 2 study in antiretroviral-naïve HIV-1 infected paediatric patients 12 to < 18 years of age and weighing at least 32 kg.
Den gennemsnitlige stigning i forhold til baseline i CD4+-celletal var 230 celler/mm3 hos patienter behandlet med E/C/F/TAF og 211 celler/mm3 hos patienter behandlet med E/C/F/TDF (p = 0,024) ved uge 48 og 326 celler/mm3 hos patienter behandlet med E/C/F/TAF og 305 celler/mm3 hos patienter behandlet med E/C/F/TDF (p = 0,06) ved uge 144.
The mean increase from baseline in CD4+ cell count was 230 cells/mm3 in E/C/F/TAF-treated patients and 211 cells/mm3 in E/C/F/TDF-treated patients (p = 0.024) at Week 48 and 326 cells/mm3 in E/C/F/TAF-treated patients and 305 cells/mm3 in E/C/F/TDF-treated patients (p = 0.06) at Week 144.
• et lavt antal blodplader (en type blodlegemer, der er med til at få blodet til at størkne)
• low platelet count (a type of blood cell involved in clotting blood)
• Hvis De for tiden tager nogen af følgende lægemidler: carbamazepin, oxcarbazepin, phenobarbital og phenytoin (anvendes til at behandle epilepsi og forebygge krampeanfald) rifabutin, rifampicin og rifapentin (anvendes til at behandle visse bakterieinfektioner som f.eks. tuberkulose)
• If you are currently taking any of the following medicines: - carbamazepine, oxcarbazepine, phenobarbital and phenytoin (used to treat epilepsy and prevent seizures) - rifabutin, rifampicin and rifapentine (used to treat some bacterial infections such as tuberculosis)
Tenofoviralafenamid er aktiv mod hepatitis B (HBV).
Tenofovir alafenamide is active against hepatitis B virus (HBV).
d Omfatter patienter, som havde ≥ 50 kopier/ml i uge 48- eller uge 144-vinduet, patienter, som afbrød behandlingen tidligt som følge af manglende eller svigtende virkning, patienter, som afbrød behandlingen af andre årsager end en bivirkning (AE), død eller manglende eller svigtende virkning, og som på tidspunktet for seponering havde en virusbelastning på ≥ 50 kopier/ml.
d Includes patients who had ≥ 50 copies/mL in the Week 48 or Week 144 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Der blev ikke rapporteret nogen anormale laboratorieværdier af grad 3-4 for ASAT/ALAT eller bivirkninger af grad 3-4 med forhøjet transaminase (se pkt.
No Grade 3-4 laboratory abnormalities for AST/ALT or Grade 3-4 adverse reactions of transaminase increased were reported (see section 5.1).
Odefsey indeholder lactosemonohydrat.
Odefsey contains lactose monohydrate.
Hos patienter, som samtidig var inficerede med hepatitis B- eller C-virus, der fik rilpivirin, var forekomsten af forhøjet leverenzym højere end hos patienter uden samtidig infektion, der fik rilpivirin.
In patients co-infected with hepatitis B or C virus receiving rilpivirine, the incidence of hepatic enzyme elevation was higher than in patients receiving rilpivirine who were not co-infected.
Ældre Dosisjustering af Odefsey er ikke nødvendig hos ældre patienter (se pkt.
Elderly No dose adjustment of Odefsey is required in elderly patients (see section 5.2).
NARKOTISKE ANALGETIKA Metadon (60-100 mg en gang dagligt, individualiseret dosis)/ rilpivirin
NARCOTIC ANALGESICS Methadone (60-100 mg once daily, individualised dose)/ Rilpivirine
Eksponeringer for emtricitabin og tenofoviralafenamid givet sammen med elvitegravir + cobicistat, som blev opnået for 24 pædiatriske patienter i alderen 12 til < 18 år, svarede til eksponeringer, som blev opnået hos behandlingsnaive voksne patienter (tabel 6).
Exposures of emtricitabine and tenofovir alafenamide given with elvitegravir + cobicistat achieved in 24 paediatric patients aged 12 to < 18 years were similar to exposures achieved in treatment-naïve adults (Table 6).
Tenofoviralafenamid absorberes hurtigt efter oral administration med maksimale plasmakoncentrationer 15-45 timer efter dosering.
Tenofovir alafenamide is rapidly absorbed following oral administration, with peak plasma concentrations occurring at 15-45 minutes post-dose.
De hyppigst rapporterede bivirkninger i kliniske studier hos behandlingsnaive patienter, som fik emtricitabin + tenofoviralafenamid i kombination med elvitegravir + cobicistat, var kvalme (11 %), diarré (7 %) og hovedpine (6 %).
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat were nausea (11%), diarrhoea (7%), and headache (6%).
3 Bivirkninger identificeret i kliniske studier af lægemidler indeholdende emtricitabin + tenofoviralafenamid.
3 Adverse reactions identified from clinical studies of emtricitabine + tenofovir alafenamide-containing products.
Vurderingen af bivirkninger er baseret på sikkerhedsdata fra alle fase 2- og 3-studier, hvor 2.396 patienter fik emtricitabin + tenofoviralafenamid sammen med elvitegravir + cobicistat som en fastdosis-kombinationstablet, samlede data fra 686 patienter, der fik rilpivirin 25 mg én gang daglig i kombination med andre antiretrovirale lægemidler i de kontrollerede studier TMC278-C209 og TMC278-C215, 754 patienter, der fik Odefsey i studierne GS-US-366-1216 og GS-US-366-1160, samt erfaringer efter markedsføring.
Assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies in which 2,396 patients received emtricitabine + tenofovir alafenamide given with elvitegravir + cobicistat as a fixed-dose combination tablet, pooled data from 686 patients who received rilpivirine 25 mg once daily in combination with other antiretroviral medicinal products in the controlled studies TMC278-C209 and TMC278-C215, 754 patients who received Odefsey in Studies GS-US-366-1216 and GS-US-366-1160, and post-marketing experience.
Hvis De tager en H2-antagonist, som f.eks. famotidin, cimetidin, nizatidin eller ranitidin, skal De tage den mindst 12 timer før eller mindst 4 timer efter Odefsey.
If you are taking an H2-antagonist such as famotidine, cimetidine, nizatidine or ranitidine, take it at least 12 hours before or at least 4 hours after Odefsey.
En patient med nyopstået resistens (M184M/I) blev identificeret i et klinisk studie af virologisk supprimerede patienter, der skiftede fra et regime indeholdende emtricitabin + tenofovirdisoproxilfumarat til E/C/F/TAF i en fastdosis kombinationstablet (GS-US-292-0109, n = 959).
One patient with emergent resistance (M184M/I) was identified in a clinical study of virologically suppressed patients who switched from a regimen containing emtricitabine + tenofovir disoproxil fumarate to E/C/F/TAF in a fixed-dose combination (FDC) tablet (GS-US-292-0109, n = 959).
Intracellulært tenofovir fosforyleres dernæst til den aktive metabolit tenofovirdiphosphat.
Intracellular tenofovir is subsequently phosphorylated to the active metabolite tenofovir diphosphate.
• Antimykotika, der anvendes til at behandle svampeinfektioner:
• Antifungal medicines used to treat fungal infections:
• føle sig oppustet
• feeling bloated
Efter virusbelastning ved baseline (kopier/ml)
By baseline viral load (copies/mL)
I studier med behandlingsnaive patienter, der fik emtricitabin + tenofoviralafenamid (FTC + TAF) eller emtricitabin + tenofovirdisoproxilfumarat (FTC + TDF), begge givet sammen med elvitegravir + cobocistat som en fastdosis-kombinationstablet, blev der i begge behandlingsgrupper observeret stigninger i forhold til baseline i faste-lipidparametrene total-kolesterol, direkte lavdensitets-lipoprotein (LDL)- og højdensitets-lipoprotein (HDL)-kolesterol og triglycerider ved uge 144.
In studies in treatment-naïve patients receiving emtricitabine + tenofovir alafenamide (FTC + TAF) or emtricitabine + tenofovir disoproxil fumarate (FTC + TDF), both given with elvitegravir + cobicistat as a fixed-dose combination tablet, increases from baseline were observed in both treatment groups for the fasting lipid parameters total cholesterol, direct low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol, and triglycerides at Week 144.
Hvis De tager et syreneutraliserende middel, som f.eks. aluminiums-/magnesiumhydroxid eller calciumcarbonat, skal De tage det mindst 2 timer før eller mindst 4 timer efter Odefsey.
If you are taking an antacid such as aluminium/magnesium hydroxide, or calcium carbonate, take it at least 2 hours before or at least 4 hours after Odefsey.
• besvær med at falde i søvn
• difficulty sleeping (insomnia)
2 Studiet blev udført med emtricitabin/rilpivirin/tenofovirdisoproxilfumarat fastdosis-kombinationstablet.
2 Study conducted with emtricitabine/rilpivirine/tenofovir disoproxil fumarate fixed-dose combination tablet.